Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Neumora Therapeutics, Inc. | Head of R&D | Common Stock | 315K | $4.75M | $15.09 | Oct 10, 2024 | Direct |
Neumora Therapeutics, Inc. | Head of R&D | Stock Option (Right to Buy) | 100K | Feb 14, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
NMRA | Neumora Therapeutics, Inc. | Oct 9, 2024 | 2 | -$208K | 4 | Oct 11, 2024 | Head of R&D |
NMRA | Neumora Therapeutics, Inc. | Sep 17, 2024 | 2 | -$493K | 4 | Sep 19, 2024 | Head of R&D |
NMRA | Neumora Therapeutics, Inc. | Sep 12, 2024 | 1 | -$377K | 4 | Sep 16, 2024 | Head of R&D |
NMRA | Neumora Therapeutics, Inc. | Feb 14, 2024 | 2 | $0 | 4 | Feb 16, 2024 | Head of R&D |
NMRA | Neumora Therapeutics, Inc. | Sep 14, 2023 | 2 | $0 | 4 | Sep 18, 2023 | Head of R&D |
NMRA | Neumora Therapeutics, Inc. | Sep 14, 2023 | 0 | $0 | 3 | Sep 14, 2023 | Head of R&D |